[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Morning Interview, Excellent vaccine news", "description": "Seriously good news", "link": "https://www.youtube.com/watch?v=Q3jjT1vdPsQ", "date_published": "2020-12-30 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Oxford Vaccine Approved", "description": "In the next few months, \nUK\nCases, + 53,135\nDeaths, + 414\n\nChAdOx1\n\nThree weeks for good level of immunity\n\nAfter this people were not hospitalised\n\nOne dose can prevent serious disease\n\nDay 22 to 3 months = 70% to 80%\n\nThree billion doses of the vaccine\n\n30 supply agreements and partner networks\n\nMedicines and Healthcare products Regulatory Agency (MHRA)\n\nHas approved two full doses of the Oxford-AstraZeneca vaccine\n\nNot enough clear data to approve the half-dose, full-dose idea\n\nFirst doses, Monday, 4th January\n\nPfizer\n\n21 days is not the minimum gap, get more people protected quicker\n\nDoctors can decide to give to pregnant and breast feeding women\n\nPeople with allergies can also be considered\n\nJoint Committee on Vaccination and Immunisation\n\nGive as many people as possible their first dose of vaccine\n \nGive as many vulnerable people some protection from Covid-19\n\nSecond dose, 4 to 12 weeks\n\nSecond dose, longer term protection.\n\nOxford already working on flexibility\n\n\nOxford/AstraZeneca Vaccine\n\nMHRA, Medicines and Healthcare Products Regulatory Agency\n\nFast-track rolling review of the vaccine since November\n\nEnters stage 4 on approval\n\nPre-orders\n\nEU, 400 million doses\n\nUK, 100 million\n\nUS, 300 million\n\nChina, 200 million\n\nJapan, 120 million\n\nBrazil, 100 million\n\nMexico, 77 million\n\nChile, 14,4 million\n\nIndonesia, 100 million\n\nAustralia, 33.6 million\n\nEgypt 30 million\n\nArgentina 32 million\n\nEcuador 5 million\n\nCanada 20 million\n\nArgentina and Mexico to produce for Latin America\n\nVaccines alliance for poorer countries, 300 million\n\nCOVAX, 170 million\n\nThree billion doses in 2021\n\nCost\n\n\u00a32\n\nTransport / storage\n\nFridge temperatures\n\nLasts six months when refrigerated at 38\u201346\u00b0F (2\u20138\u00b0C)\n\n\nEfficacy\n\nPascal Soriot, winning formula\n\n62%    70% 90% 100% \n\nStrong response in older adults\n\nManufacturing\n\nKeele, UK\n\nBelgium\n\nIndia, Serum Institute, 1 billion doses\n\nMelbourne, Australia\n\nThailand, South East Asia\n\nNetherlands and Germany\n\nAcross Europe\n\nShenzhen, China\n\nUS\n\nAlbuquerque, New Mexico\n\nMaryland\n\nRussia\n\nMexico\n\n\nUK, 100 million\n\nFour million ready to go\n\nFifteen million ready to put into vials\n\nMass rollout starts 4th January\n\nOne million people per week\n\nMass rollout\n\nImportant that no screening is required\n\nReactogenicity does not appear to be affected by the presences of antibodies to coronavirus.\n\nUS\n\nMr. Biden, 100 million shots in first 100 days\n\nPublished evidence base\n\nAZ press release\n\nhttps://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html\n\nOxford vaccine, home site\n\nhttps://www.ovg.ox.ac.uk\n\nThe Oxford Coronavirus Site\n\nhttps://www.research.ox.ac.uk/Area/coronavirus-research/vaccine\n\nThe Jenner Institute\n\nhttps://www.jenner.ac.uk", "link": "https://www.youtube.com/watch?v=8Pj4_aK-j8I", "date_published": "2020-12-30 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vaccination, excellent news", "description": "Mass rollout in the UK from Monday, 4th January", "link": "https://www.youtube.com/watch?v=l3B7PyXblXY", "date_published": "2020-12-30 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "New viral strain spreads through UK", "description": "Variant of Concern (VOC), 202012/01\n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948152/Technical_Briefing_VOC202012-2_Briefing_2_FINAL.pdf\n\nTwo week delay on full genome sequencing\n\nAbsence of amino acids 69 and 70 (\u039469-70) \n\nShows up on PCR test\n\nS gene target failure (SGTF) \n\nCohort studies\n\nIs there a greater risk of reinfections with the new variant compared to the wild-type virus?\n\n20 September and 15 December 2020 \n\nDefined by a 90 day gap\n\nNew Variant case group\n\nTwo reinfections\n\n1.13 per 1000 cases\n\nWild-type comparator cases\n\nThree reinfections\n\n1.70 per 1000 cases\n\nRate of detected re-infections\n\nReinfected with wild-type comparator\n\n0.60 per 1000 \n\nReinfected with new variant\n\n0.61 per 1000\n\nDoes this non-difference have implications for vaccine efficacy?\n\nYes, the same immune response generates immunity to both new variant AND wild viral strains\n\nDoes the new variant lead to more severe illness and deaths than the wild-type virus?\n\nIllness severity\n\nNo statistically significant difference in hospitalisation\n\nor 28-day case fatality\n\nDoes the new variant lead to more hospitalisations than the wild-type virus?\n\nData from positive 3,538 cases\n\n20 September to 15 December 2020 \n\n42 admitted\n\nNew variant group\n\n16 admissions (0.9%)\n\nWild-type comparator cases\n\n26 admissions, (1.5%)\n\nDifference was not significant\n\nNumbers likely rise in both groups with time\n \nIs the new variant more deadly than the wild-type virus?\n\nThe 28-day case fatality\n\nOnly 2,700 cases with a full 28 days elapsed since the specimen date\n\nNew variant cases\n\n12 of 1,340 (0.89%) died\n\nWild-type comparator cases\n\n10 of 1,360 (0.73%) died\n\nOdds ratio:1.21, p=0.65\n\nDifference was not significant \n\nIs the new variant more transmissible than the wild-type virus?\n\nSecondary attack rates \n\n5 October and 6 December 2020\n\n1,105,388 cases reported to Test and Trace\n\n46,237 (4.2%) had genomic sequencing data\n\n1,978 had the variant (VOC 202012/01), 4.3% of those with sequencing data. \n\nA total of 228,361 of all contacts notified by cases in this period became cases \n\n15.1% among those whose index case was confirmed to have the VOC 202012/01 \n\n9.8% among those whose index case was sequenced and confirmed with other variants \n\nIs this increased transmissibility consistent with previous data?\n\nEstimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England \n\nCentre for Mathematical Modelling of Infectious Diseases London School of Hygiene and Tropical Medicine \n\nhttps://cmmid.github.io/topics/covid19/reports/uk-novel-variant/2020_12_23_Transmissibility_and_severity_of_VOC_202012_01_in_England.pdf\n\nVOC 202012/01 is 56% more transmissible \n\n95% credible interval across three regions 50-74%", "link": "https://www.youtube.com/watch?v=RW7A-6H_qNk", "date_published": "2020-12-29 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]